Advertisement

ATRS

Antares Pharma, Inc.

Healthcare

Set alert

Price alert · ATRS

All alert types
5.59 0.00 0.00%
As of Apr 24, 2025
5.58 Day range 5.59

52-week range unavailable

Open
5.59
Prev close
5.59
Mkt cap
955.06M
Vol
1.76M
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
5.58
High
5.59
Forward P/E
25.41
Beta
1.15
Short ratio
0.41
Inst. own
62.83%
Dividend
0.00
Ex-div date
Earnings
May 10, 2022
50-d avg
4.90
200-d avg
3.92
1y target
5.95

2Y chart

Chart tools
Interval
ATRS two-year price chart3.113.734.354.985.60Nov 21Dec 21Jan 22Mar 22Apr 22May 22

Key statistics

Market cap
955.06M
Enterprise value
918.34M
Trailing P/E
24.09
Forward P/E
25.41
PEG ratio
0.89
Price / sales
5.21
Price / book
5.43
EPS (TTM)
0.232
Beta
1.15
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
21.90%
Revenue (TTM)
183.46M
Revenue growth
-1.30%
Free cash flow
-19.87M
Total cash
62.21M
Total debt
25.49M
Return on equity
26.61%
Shares outstanding
170.85M
Short % of float
2.86%
50-day average
4.90
200-day average
3.92

Analyst view

Consensus: hold

Hold
Price target (mean) 5.95 +6.4% upside
Target (low)
5.60
Target (mean)
5.95
Target (high)
7.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
  • Strong buy3
  • Buy2
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

May 10, 2022

Expected May 10, 2022. Consensus EPS estimate 0.01.

Earnings history

Financials — quick view

All financials
ATRS Revenue — quarterly 41.56M
2018-Q2 20182018-Q3 20182018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 2022
ATRS Net income — quarterly -2.32M
2018-Q2 20182018-Q3 20182018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 2022
ATRS EPS — quarterly -0.01
2018-Q2 20182018-Q3 20182018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 2022

Earnings

ATRS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 10, 2022Mar 1, 20220.00———
Mar 3, 2022Dec 1, 20210.01———
Nov 4, 2021Sep 1, 20210.03———
Aug 5, 2021Jun 1, 20210.02———
May 6, 2021Mar 1, 20210.02———
Mar 2, 2021Dec 1, 20200.04———

Upgrades / downgrades

ATRS analyst upgrades and downgrades
DateFirmActionFromTo
Apr 14, 2022Truist SecuritiesdownBuyHold
Apr 14, 2022Ladenburg ThalmanndownBuyNeutral
Apr 14, 2022Raymond JamesdownStrong BuyMarket Perform
Apr 14, 2022HC Wainwright & Co.downBuyNeutral
Apr 14, 2022Piper SandlerdownOverweightNeutral
Nov 5, 2021HC Wainwright & Co.main—Buy

About Antares Pharma, Inc.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States

News

Your note

Sign in to keep a note on ATRS — it syncs with the Stock Master app.

Insider holders

ATRS insider holders
InsiderRelationLatest transactionDateShares held
APPLE ROBERT FChief Executive OfficerStock Award(Grant)Mar 2, 20222,488,360
GARRITY THOMAS JOHNDirectorStock Award(Grant)Jun 9, 2021249,858
GRAHAM PETER JGeneral CounselStock Award(Grant)Mar 2, 2022616,609
GREENLEAF PETER SDirectorStock Award(Grant)Jun 9, 202179,645
GUETH ANTON GDirectorSaleJul 7, 2021467,577
JACOB LEONARD SDirectorStock GiftOct 25, 2021170,575

Institution ownership

ATRS institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.00%11,954,17149.01MMar 30, 2022
Rubric Capital Management LP6.38%10,900,00044.69MMar 30, 2022
Vanguard Group, Inc. (The)5.06%8,643,15535.44MMar 30, 2022
Sargent Investment Group, LLC2.14%3,663,27515.02MMar 30, 2022
Amundi2.02%3,451,78914.15MMar 30, 2022
State Street Corporation2.02%3,449,45714.14MMar 30, 2022

Fund ownership

ATRS fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.69%4,597,59716.41MDec 30, 2021
iShares Russell 2000 ETF2.22%3,796,97913.29MFeb 27, 2022
Vanguard Extended Market Index Fund1.21%2,059,0337.35MDec 30, 2021
iShares Russell 2000 Growth ETF0.82%1,395,3245.72MMar 30, 2022
Fidelity Small Cap Index Fund0.75%1,283,4724.49MFeb 27, 2022
Fidelity Extended Market Index Fund0.52%892,0563.12MFeb 27, 2022
Advertisement